-
Hydroxycinnamic Acids, COPII, and cGAS-STING
2026-09-10
The reference study identifies the Sec24 B-site of the COPII coat complex as a molecular target of cinnamic, caffeic, and ferulic acids, linking cargo sorting to cGAS-STING-dependent inflammation. Structural, cellular, and diabetic mouse experiments indicate that blocking STING trafficking can improve steatosis, glucose regulation, lipid homeostasis, and hepatic injury, while also defining important boundaries for translation.
-
Tivozanib (AV-951) for Reliable Cell Assays
2026-09-09
Learn how Tivozanib (AV-951), SKU A2251, can support more interpretable viability, proliferation, and cytotoxicity experiments through disciplined formulation, exposure, and response analysis. This scenario-based guide connects VEGFR biology with practical assay design for biomedical researchers.
-
Antiseptics for Burns: Evidence and Research Implications
2026-09-09
The 2017 Cochrane review examined whether topical antiseptics improve healing, infection outcomes, pain, and safety in burn wounds, while emphasizing the uncertainty and heterogeneity of the available evidence. Its main practical contribution is a structured framework for separating antimicrobial activity from clinically meaningful wound-healing benefit.
-
In Vitro Cancer Drug Response: Beyond Viability
2026-09-08
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating proliferative arrest from cell killing and considering their timing, the work offers a more precise framework for interpreting in vitro drug-response experiments.
-
TET2 Metabolite Binding and Regulation by STD NMR
2026-09-08
Zhang, Cheng, and Ye present an integrated workflow that combines biochemical activity assays with saturation transfer difference NMR to distinguish metabolite binding from functional regulation of human TET2. The protocol validates known TET2 activators and inhibitors and identifies glyoxylate as a directly binding, potentially inhibitory metabolite, providing a reproducible framework for metabolism–epigenetics research.
-
Prochlorperazine-Induced Neuroleptic Malignant Syndrome
2026-09-07
This case report shows that prochlorperazine can trigger neuroleptic malignant syndrome (NMS) in an older adult even at a standard prescribed dose and without marked creatine phosphokinase elevation. Its practical contribution is to emphasize medication history, bedside neurological findings, differential diagnosis, and early benzodiazepine- and amantadine-based management when laboratory results are not strongly abnormal.
-
Tunicamycin Workflows for ER Stress Research
2026-09-05
Tunicamycin combines upstream N-glycosylation blockade with a practical ER stress model for macrophage, T-cell, and tissue studies. This guide translates the reference study into controlled workflows, assay controls, and troubleshooting decisions that improve mechanistic interpretation.
-
Smoothened Agonist (SAG) Assay Guide
2026-09-05
This scenario-driven guide explains how Smoothened Agonist (SAG), SKU B5837, can improve interpretation of Hedgehog pathway activation, viability, proliferation, and mitochondrial assays. It combines formulation guidance, concentration context, developmental-model evidence, and practical vendor-selection criteria for more defensible laboratory workflows.
-
Diphenyleneiodonium Chloride in ROS Assays
2026-09-04
Diphenyleneiodonium chloride (DPI) is more than a generic oxidant inhibitor: it is a context-dependent probe for redox enzyme function and cAMP signaling modulation. This guide connects DPI assay design with new evidence on iron-, ROS-, and ferroptosis-linked plant immunity while emphasizing causal interpretation and experimental controls.
-
SAR405 Reveals Vps34’s Nuclear DNA Repair Axis
2026-09-04
SAR405 is a selective Vps34 inhibitor that connects PI3P depletion with autophagy, vesicle trafficking, lysosome function, and nuclear mismatch repair. This article presents a compartment-aware assay strategy that distinguishes organelle phenotypes from emerging genome-maintenance biology.
-
Trichostatin A (TSA): Practical Assay Guide
2026-09-03
A scenario-based guide to using Trichostatin A (TSA), SKU A8183, in cell viability, proliferation, cytotoxicity, and differentiation workflows. It connects HDAC biology with solvent handling, dose selection, orthogonal readouts, and evidence-based vendor evaluation.
-
Niclosamide: Assay Design Beyond STAT3 Inhibition
2026-09-02
Niclosamide supports a layered strategy for connecting STAT3 Tyr-705 inhibition with transcriptional, cell-cycle, and apoptotic readouts. This article adds a practical cross-domain perspective by using a molluscicide study to clarify assay controls, endpoint selection, and evidence boundaries.
-
Fzd5 Couples Cholesterol to Wnt/β-Catenin Signaling
2026-09-02
The reference study identifies Fzd5 as a cholesterol-responsive Wnt receptor that links lipid metabolism to receptor palmitoylation, plasma-membrane trafficking, and β-catenin signaling in pancreatic cancer. Its findings establish a mechanistic basis for targeting the cholesterol–Fzd5 axis while also defining important limits for translating this pathway to other tumors.
-
Resazurin Cell Viability Assay Kit in Bone Research
2026-09-02
Learn how the Resazurin Cell Viability Assay Kit can strengthen pharmacology workflows for Wnt-driven bone disease models. This article translates findings from a 2025 sclerosteosis study into practical assay design, interpretation, and validation decisions.
-
Regorafenib Targets RRM2 in Melanoma
2026-09-01
A 2024 iScience study identifies RRM2 as a functionally important downstream mediator of Regorafenib activity in melanoma and connects its reduction with ERK/E2F3 signaling, apoptosis, and weaker malignant behavior. The work provides a mechanistic framework for combining viability, motility, transcriptomic, rescue, and tumor xenograft models in melanoma-focused cancer biology research.